While combining miR‐34b with JQ1, a BRD4 inhibitor, could present a therapeutic option for breast cancer patients, this approach warrants further investigation, particularly in the context of TNBC, where the oncogenic role of miR‐34b must be carefully considered. Here, BRD4 is linked to breast cancer.